HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker

Neoplasia (United States)

Volumn 16, Issue 1, 2014, Pages 31-42

  Sconocchia, Giuseppe ^a   Eppenberger Castori, Serenella ^b   Zlobec, Inti ^c   Karamitopoulou, Eva ^c,d   Arriga, Roberto ^e   Coppola, Andrea ^e   Caratelli, Sara ^a   Spagnoli, Giulio Cesare ^b   Lauro, Davide ^e   Lugli, Alessandro ^c   Han, Junyi ^b,f   Iezzi, Giandomenica ^b   Ferrone, Cristina ^g   Ferlosio, Amedeo ^e   Tornillo, Luigi ^b   Droeser, Raoul ^b   Rossi, Piero ^e   Attanasio, Antonio ^e   Ferrone, Soldano ^g   Terracciano, Luigi ^b  

^a INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f TONGJI UNIVERSITY   (China)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; INTERLEUKIN 1BETA; INTERLEUKIN 6;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CLINICAL FEATURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; IN VITRO STUDY; PATHOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TISSUE MICROARRAY;

CARCINOMA; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DP ANTIGENS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTESTINAL MUCOSA; MALE; MONOCYTES; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS;

EID: 84900440773     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.131568     Document Type: Article

References (61)

1. Fearon ER (2011). Molecular genetics of colorectal cancer. Annu Rev Pathol 6, 479-507.
2. Smyrk TC, Watson P, Kaul K, and Lynch HT (2001). Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 91, 2417-2422.
3. Lazzaro B, Anderson AE, Kajdacsy-Balla A, and Hessner MJ (2001). Antigenic characterization of medullary carcinoma of the breast: HLA-DR expression in lymph node positive cases. Appl Immunohistochem Mol Morphol 9, 234-241.
4. Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F, Muller M, Kramer B, Missiou A, Sauter M, et al. (2006). Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 12, 4163-4170.
5. Taramelli D, Fossati G, Mazzocchi A, Delia D, Ferrone S, and Parmiani G (1986). Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. Cancer Res 46, 433-439.
6. Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, Boddi V, Reali UM, and Giannotti B (1997). In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 7, 313-321.
7. Trieb K, Lechleitner T, Lang S, Windhager R, Kotz R, and Dirnhofer S (1998). Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma. Pathol Res Pract 194, 679-684.
8. Hilders CG, Houbiers JG, van Ravenswaay Claasen HH, Veldhuizen RW, and Fleuren GJ (1993). Association between HLA-expression and infiltration of immune cells in cervical carcinoma. Lab Invest 69, 651-659.
9. Esteban F, Ruiz-Cabello F, Concha A, Pèrez-Ayala M, Sànchez-Rozas HA, and Garrido F (1990). HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx. Clin Exp Metastasis 8, 319-328.
10. Lovig T, Andersen SN, Thorstensen L, Diep CB, Meling GI, Lothe RA, and Rognum TO (2002). Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. Br J Cancer 87, 756-762.
11. de Bruin EC, van de Velde CJ, van Krieken JH, Marijnen CA, and Medema JP (2008). Epithelial human leukocyte antigen-DR expression predicts reduced recurrence rates and prolonged survival in rectal cancer patients. Clin Cancer Res 14, 1073-1079.
12. Gutierrez J, Lòpez-Nevot MA, Cabrera T, Oliva R, Esquivias J, Ruiz-Cabello F, and Garrido F (1987). Class I and II HLA antigen distribution in normal mucosa, adenoma and colon carcinoma: relation with malignancy and invasiveness. Exp Clin Immunogenet 4, 144-152.
13. Matsushita K, Takenouchi T, Shimada H, Tomonaga T, Hayashi H, Shioya A, Komatsu A, Matsubara H, and Ochiai T (2006). Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: possible involvement of c-myc suppression by interferon-γ in situ. Cancer Sci 97, 57-63.
14. Morita M, Tanaka K, Kawanishi H, Tsuji M, Ookusa T, Takada H, Okamura A, and Hioki K (1995). Immunohistochemically demonstrated expression of HLA-DR antigen in colorectal adenocarcinomas and its relation to clinicopathological features. J Surg Oncol 59, 233-238.
15. Walsh MD, Dent OF, Young JP, Wright CM, Barker MA, Leggett BA, Bokey L, Chapuis PH, Jass JR, and Macdonald GA (2009). HLA-DR expression is associated with better prognosis in sporadic Australian clinicopathological stage C colorectal cancers. Int J Cancer 125, 1231-1237.
16. Moller P, Momburg F, Koretz K, Moldenhauer G, Herfarth C, Otto HF, Hämmerling GJ, and Schlag P (1991). Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cancer Res 51, 729-736.
17. Mulder WM, Stern PL, Stukart MJ, de Windt E, Butzelaar RM, Meijer S, Ader HJ, Claessen AM, Vermorken JB, Meijer CJ, et al. (1997). Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients. Clin Cancer Res 3, 1923-1930.
18. Diederichsen AC, Hjelmborg J, Christensen PB, Zeuthen J, and Fenger C (2003). Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 52, 423-428.
19. Momburg F, Degener T, Bacchus E, Moldenhauer G, Hammerling GJ, and Moller P (1986). Loss of HLA-A,B,C and de novo expression of HLA-D in colorectal cancer. Int J Cancer 15, 179-184.
20. Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E, Patsouris ES, Peros G, Horcic M, Tornillo L, et al. (2011). Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer 128, 2663-2672.
21. Michel S, Linnebacher M, Alcaniz J, Voss M, Wagner R, Dippold W, Becker C, von Knebel Doeberitz M, Ferrone S, and Kloor M (2010). Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. Int J Cancer 127, 889-898.
22. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, and Kallioniemi OP (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4, 844-847.
23. Temponi M, Kekish U, Hamby CV, Nielsen H, Marboe CC, and Ferrone S (1993). Characterization of anti-HLA class II monoclonal antibody LGII- 612.14 reacting with formalin fixed tissues. J Immunol Methods 161, 239-256.
24. Boyum A (1968). Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 21(suppl 97), 77-89.
25. Kammula US, Lee KH, Riker AI, Wang E, Ohnmacht GA, Rosenberg SA, and Marincola FM (1999). Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 163, 6867-6875.
26. Mengus C, Le MC, Trella E, Yousef K, Bubendorf L, Provenzano M, Bachmann A, Heberer M, Spagnoli GC, and Wyler S (2011). Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J Transl Med 9, 162.
27. -ΔΔCT method. Methods 25, 402-408.
28. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348, 203-213.
29. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, and Palmqvist R (2007). High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 13, 1472-1479.
30. Sconocchia G, Spagnoli GC, Del Principe D, Ferrone S, Anselmi M, Wongsena W, Cervelli V, Schultz-Thater E, Wyler S, Carafa V, et al. (2009). Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves β2-integrin-mediated interaction. Neoplasia 11, 662-671.
31. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. (2005). Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353, 2654-2666.
32. Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, and Spagnoli GC (2012). Melanoma cells inhibit NK cell functions-letter. Cancer Res 72, 5428-5429.
33. Droeser RA, Hirt C, Eppenberger-Castori S, Zlobec I, Viehl CT, Frey DM, Nebiker CA, Rosso R, Zuber M, Amicarella F, et al. (2013). High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. PLoS One 8, e64814.
34. Sconocchia G, Del Principe D, and Barrett AJ (2007). CD16low/negative tumorinfiltrating lymphocyte: lymphoid or myeloid in origin? Clin Cancer Res 13, 1620.
35. Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, Oertli D, Kettelhack C, Terracciano L, and Tornillo L (2010). High frequency of tumorinfiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 126, 2635-2643.
36. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, et al. (2013). Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 49, 2233-2242.
37. Schwartz R, Momburg F, Moldenhauer G, Dorken B, and Schirrmacher V (1985). Induction of HLA class-II antigen expression on human carcinoma cell lines by IFN-Gamma. Int J Cancer 35, 245-250.
38. Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, Tuppurainen K, Makela J, Karttunen TJ, and Mäkinen MJ (2005). Inflammation and prognosis in colorectal cancer. Eur J Cancer 41, 2645-2654.
39. Algars A, Irjala H, Vaittinen S, Huhtinen H, Sundström J, Salmi M, Ristamäki R, and Jalkanen S (2012). Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int J Cancer 131, 864-873.
40. Edin S, Wikberg ML, Dahlin AM, Rutegård J, Oberg A, Oldenborg PA, and Palmqvist R (2012). The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 7, e47045.
41. Kinouchi M, Miura K, Mizoi T, Ishida K, Fujibuchi W, Sasaki H, Ohnuma S, Saito K, Katayose Y, Naitoh T, et al. (2012). Infiltration of CD40-positive tumor-associated macrophages indicates a favorable prognosis in colorectal cancer patients. Hepatogastroenterology 60, 83-88.
42. Lackner C, Jukic Z, Tsybrovskyy O, Jatzko G, Wette V, Hoefler G, Klimpfinger M, Denk H, and Zatloukal K (2004). Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch 445, 160-167.
43. Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, Miconnet I, Lemonnier FA, and Kosmatopoulos K (2003). EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Cancer Res 63, 8476-8480.
44. Bohm CM, Hanski ML, Stefanovic S, Rammensee HG, Stein H, Taylor- Papadimitriou J, Riecken EO, and Hanski C (1998). Identification of HLA-A2- restricted epitopes of the tumor-associated antigen MUC2 recognized by human cytotoxic T cells. Int J Cancer 75, 688-693.
45. Koesters R, Linnebacher M, Coy JF, Germann A, Schwitalle Y, Findeisen P, and von Knebel Doeberitz M (2004). WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Int J Cancer 109, 385-392.
46. Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, et al. (2003). Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci USA 100, 3398-3403.
47. Umano Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, and Tanimura H (2001). Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br J Cancer 84, 1052-1057.
48. Vissers JL, De Vries IJ, Schreurs MW, Engelen LP, Oosterwijk E, Figdor CG, and Adema GJ (1999). The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 59, 5554-5559.
49. Banchereau J and Steinman RM (1998). Dendritic cells and the control of immunity. Nature 392, 245-252.
50. Donath MY, Böni-Schnetzler M, Ellingsgaard H, and Ehses JA (2009). Islet inflammation impairs the pancreatic β-cell in type 2 diabetes. Physiology (Bethesda) 24, 325-331.
51. Sconocchia G, Campagnano L, Adorno D, Iacona A, Cococcetta NY, Boffo V, Amadori S, and Casciani CU (2001). CD44 ligation on peripheral blood polymorphonuclear cells induces interleukin-6 production. Blood 97, 3621-3627.
52. Gabay C (2006). Interleukin-6 and chronic inflammation. Arthritis Res Ther 8(suppl 2), S3.
53. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, et al. (2009). IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitisassociated cancer. Cancer Cell 15, 103-113.
54. Mantovani A, Allavena P, Sica A, and Balkwill F (2008). Cancer-related inflammation. Nature 454, 436-444.
55. Richards CH, Leitch EF, Horgan PG, Anderson JH, McKee RF, and McMillan DC (2010). The relationship between patient physiology, the systemic inflammatory response and survival in patients undergoing curative resection of colorectal cancer. Br J Cancer 103, 1356-1361.
56. Garrity-Park MM, Loftus EV Jr, Sandborn WJ, Bryant SC, and Smyrck TC (2009). MHC class II alleles in ulcerative colitis-associated colorectal cancer. Gut 58, 1226-1233.
57. Cabrera T, Ruiz-Cabello F, and Garrido F (1995). Biological implications of HLA-DR expression in tumors. Scand J Immunol 41, 398-406.
58. Hanafusa T, Pujol-Borrel R, Chiovato R, Russel RCG, Doniach D, and Bottazzo GF (1983). Aberrant expression of HLA-DR antigen on thyrocytes in Graves' disease: relevance for autoimmunity. Lancet 2, 1111-1115.
59. Bottazzo GF, Dean BM, NcNally JM, Mackay EH, Swifr PGF, and Gamble DR (1985). In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 313, 353-360.
60. Ballardini G, Mirakian R, Bianchi FB, Pisi E, Doniach D, and Bottazzo GF (1984). Aberrant expression of HLA-DR antigens on bile duct epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet 2, 1009-1013.
61. Trinh KR, Vasuthasawat A, Steward KK, Yamada RE, Timmerman JM, and Morrison SL (2013). Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas. J Immunother 36, 305-318.